Reported Sunday, GSK Licenses Hengrui Pharma's HRS-9821 For Chronic Obstructive Pulmonary Disease, Adds Option Rights To 11 Additional Programs Post-Phase I

-0.93% Pre

GlaxoSmithKline plc Sponsored ADR

GSK

48.78

49.34

-0.93%

+1.15% Pre

Includes license for potential best-in-class PDE3/4 inhibitor (HRS-9821) in clinical development for treatment of COPD
Additional 11 programmes to be developed by Hengrui Pharma and optioned by GSK following phase I completion

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.